Nektar Therapeutics (NKTR) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $73.48 +0.63%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $21.49 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
- L3Harris CEO steps down amid conduct review, shares drop
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
